Bently P Doonan, MD - Research

Research at a glance

Top areas of exploration

Antigen Presentation , 4 publications
Melanoma , 3 publications
Autophagy , 3 publications
CD4-Positive T-Lymphocytes , 3 publications

Research activity

16 publications

272 citations

Why is this important?

Active clinical trials

Oral IRAK-4 inhibitor CA-4948 in combination with Pembrolizumab following stereotactic radiosurgery

This phase I/II trial will investigate the use of the novel oral IRAK-4 inhibitor CA-4948 in combination with pembrolizumab therapy following stereotactic radiosurgery in patients with melanoma brain metastases (MBM). The investigators hypothesize…

Investigator: Bently P Doonan
Status: Accepting Candidates
Ages: 18 Years - 99 Years
Sexes: All

Pembro With Investigational Agents or Pembro Alone in First Line (1L) Advanced Melanoma

Substudy 02B is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02B is to evaluate the safety and efficacy of investigational…

Investigator: Bently P Doonan
Status: Accepting Candidates
Ages: 18 Years - 120 Years
Sexes: All

My publications

16 publications

2022

GILT Expression in Human Melanoma Cells Enhances Generation of Antigenic Peptides for HLA Class II-Mediated Immune Recognition.

International journal of molecular sciences

PubMed • Publisher's site

2022

Peptide Modification Diminishes HLA Class II-restricted CD4+ T Cell Recognition of Prostate Cancer Cells.

International journal of molecular sciences

PubMed • Publisher's site

2019

Endoplasmic reticulum stress, autophagic and apoptotic cell death, and immune activation by a natural triterpenoid in human prostate cancer cells.

Journal of cellular biochemistry

PubMed • Publisher's site

2018

Autophagy-dependent crosstalk between GILT and PAX-3 influences radiation sensitivity of human melanoma cells.

Journal of cellular biochemistry

PubMed • Publisher's site

2015

Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design.

Journal of clinical & cellular immunology

PubMed

My Location

Bently P Doonan, MD : Research

Research at a glance

Top areas of exploration

Research activity

Active clinical trials

My publications

GILT Expression in Human Melanoma Cells Enhances Generation of Antigenic Peptides for HLA Class II-Mediated Immune Recognition.

Peptide Modification Diminishes HLA Class II-restricted CD4+ T Cell Recognition of Prostate Cancer Cells.

Endoplasmic reticulum stress, autophagic and apoptotic cell death, and immune activation by a natural triterpenoid in human prostate cancer cells.

Autophagy-dependent crosstalk between GILT and PAX-3 influences radiation sensitivity of human melanoma cells.

Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design.

Provide website feedback?

Site Feedback

Research at a glance

Top areas of exploration

Research activity

Active clinical trials

My publications

Filter publications

GILT Expression in Human Melanoma Cells Enhances Generation of Antigenic Peptides for HLA Class II-Mediated Immune Recognition.

Peptide Modification Diminishes HLA Class II-restricted CD4+ T Cell Recognition of Prostate Cancer Cells.

Endoplasmic reticulum stress, autophagic and apoptotic cell death, and immune activation by a natural triterpenoid in human prostate cancer cells.

Autophagy-dependent crosstalk between GILT and PAX-3 influences radiation sensitivity of human melanoma cells.

Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design.

Provide website feedback?

Site Feedback